Myeloma escape from immunity: an “inside” job. Rapoport AP. Blood. 2015 Sep 17;126(12):1401-3. doi: 10.1182/blood-2015-07-659490. Antibody based immunotherapy for multiple myeloma: It’s about time. Sher T et al, Leuk Lymphoma. 2015 Sep 16:1-17. [Epub ahead of print]. Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies. Karp Leaf R et al. Curr Hematol Malig Rep. 2015 Sep 4. [Epub ahead of…Details
Early Surgical Occipito-Cervical Stabilization for Plasma Cell Neoplasms at the Cranio-Cervical Junction – Systematic Review and Proposal of a Treatment Algorithm. Ahmadi SA et al. Spine J. 2015 Sep 24. pii: S1529-9430(15)01442-4. doi: 10.1016/j.spinee.2015.09.032. [Epub ahead of print]. Pathologic sternal involvement is a potential risk factor for severe sagittal plane deformity in multiple myelomawith concomitant thoracic fractures. Butler JS et…Details
Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma. Lin TL et al. J Clin Apher. 2015 Sep 5. doi: 10.1002/jca.21421. [Epub ahead of print]. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. Jagirdar N et al. Transfusion. 2015 Sep 2.…Details
The IMWG report on the newly developed revised version of the International Staging System (R-ISS) which incorporates chromosomal abnormalities to develop a more powerful staging system for stratifying myeloma patients.
IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay. Djidjik R et al. Pathol Biol (Paris). 2015 Aug 17. pii: S0369-8114(15)00057-7. doi: 10.1016/j.patbio.2015.06.002. [Epub ahead of print]. Patient dose evaluation for the whole-body low-dose multidetector CT (WBLDMDCT) skeleton study in multiple myeloma (MM). Cretti F et al. Radiol Med. 2015 Aug 19. [Epub ahead of print]. Clinical…Details
Lenalidomide is safe and active in waldenström macroglobulinemia. Fouquet G et al. Am J Hematol. 2015 Aug 18. doi: 10.1002/ajh.24175. [Epub ahead of print]. Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine. Simeon V et al. Int J Mol Sci. 2015 Jul 30;16(8):17514-34. doi: 10.3390/ijms160817514. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and…Details
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. Lokhorst HM et al. N Engl J Med. 2015 Aug 26. [Epub ahead of print]. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Kumar SK et al. Blood Cancer J. 2015 Aug 14;4:e338. doi: 10.1038/bcj.2015.60. Panobinostat: the small molecule metalloenzyme inhibitor with marvelous anticancer activity. Ganai SA. Curr Top Med…Details
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. Lionetti M et al. Oncotarget. 2015 Jul 20. [Epub ahead of print]. The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM. Follin-Arbelet V et al. Sci Rep. 2015 Aug 26;5:13001. doi: 10.1038/srep13001. Notch signaling deregulation in multiple myeloma: A rational molecular target. Colombo M et…Details
Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.
Yadav P et al. Eur J Haematol. 2015 Aug 6. doi: 10.1111/ejh.12644. [Epub ahead of print].